e-learning
resources
Vienna 2009
Tuesday, 15.09.2009
Pulmonary circulation II
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension
C. Dimitropoulou, M. L. Meadows, C. Snead, S. A. Barman, J. D. Catravas (Augusta, United States Of America)
Source:
Annual Congress 2009 - Pulmonary circulation II
Session:
Pulmonary circulation II
Session type:
Thematic Poster Session
Number:
3936
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
C. Dimitropoulou, M. L. Meadows, C. Snead, S. A. Barman, J. D. Catravas (Augusta, United States Of America). The heat shock protein 90 inhibitor, 17-AAG, ameliorates pulmonary arteriolar and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension. Eur Respir J 2009; 34: Suppl. 53, 3936
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Bosentan combined with sildenafil prevents right ventricular hypoxia in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pathophysiology of pulmonary hypertension
Year: 2008
Urocortin-2 improves right ventricular function and attenuates experimental pulmonary arterial hypertension
Source: International Congress 2018 – Pulmonary hypertension: therapy
Year: 2018
Effect of sitaxentan on haemodynamics and right ventricular hypertrophy in monocrotaline-induced pulmonary arterial hypertension (PAH)
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
Lodenafil improves hemodynamics and right ventricular remodeling in monocrotaline-induced model of pulmonary arterial hypertension in rats
Source: Annual Congress 2010 - Experimental pulmonary hypertension
Year: 2010
Improvement of exercise capacity in monocrotaline induced pulmonary hypertension by the phosphodiesterase inhibitor Vardenafil
Source: Annual Congress 2006 - Signalisation in the pulmonary vasculature: new pathways and wrong signals
Year: 2006
Carvedilol partially reverses maladaptive remodeling and improves function of the right ventricle (RV) in experimentally-induced pulmonary arterial hypertension (PAH)
Source: Annual Congress 2009 - Pathobiology of pulmonary vascular diseases
Year: 2009
Increased right ventricular cardiomyocyte stiffness in patients with pulmonary arterial hypertension
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and cell biology
Year: 2012
How prostacyclin therapy improves right ventricular function in pulmonary arterial hypertension
Source: Eur Respir J, 50 (2) 1700764; 10.1183/13993003.00764-2017
Year: 2017
Combining bosentan and sildenafil improves mitochondrial capacity and restores right ventricular contractility in established pulmonary hypertension
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by hsp90 inhibitors
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012
2-Ethoxyestradiol inhibits vascular and cardiac remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2007 - Cellular and molecular aspects of pulmonary hypertension
Year: 2007
Right ventricular and pulmonary vascular interaction in pulmonary arterial hypertension
Source: Annual Congress 2008 - Pulmonary hypertension in connective tissue diseases
Year: 2008
Cystamine and sildenafil in treatment of right ventricular hypertrophy in rats with pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary hypertension II
Year: 2008
HDAC inhibitor quisinostat reduces pulmonary vascular remodeling in experimentally induced pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015
ACE2 activation improves pulmonary endothelial function and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011
Vascular and right ventricular remodelling in chronic thromboembolic pulmonary hypertension
Source: Eur Respir J 2013; 41: 224-232
Year: 2013
2-Methoxyestrone inhibits vascular remodeling and attenuates monocrotaline-induced pulmonary hypertension
Source: Annual Congress 2008 - Pulmonary vascular biology
Year: 2008
In a model of genetic pulmonary hypertension, VIP attenuates pulmonary vascular remodeling and right ventricular hypertrophy
Source: Annual Congress 2007 - Pathogenesis and novel therapeutic targets in pulmonary hypertension
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept